

e-ISSN 2329-0358 © Ann Transplant, 2021; 26: e927025 DOI: 10.12659/AOT.927025

Received: 2020.06.24 Accepted: 2020.11.17 Available online: 2020.12.04 Published: 2021.01.26		Number of Bronchoscop Lung Transplant Recipie Respiratory Function As Function Tests	nts Correlates with
Authors' Contribution: Study Design A Data Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G	ACEF 1,2 BCEF 1,2 BD 1,2 BC 1,2 BEF 1,2 BCD 1,2 AF 1,2 AF 1,2 AF 1,2	Magdalena Latos Maciej Urlik Remigiusz Antończyk Martyna Gawęda Anastazja Pandel Tomasz Stącel Piotr Przybyłowski Marian Zembala	 Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia, Katowice, Poland Silesian Center for Heart Diseases, Zabrze, Poland First Chair of General Surgery, Jagiellonian University, Crcaow, Poland
Correspondin Source of	g Author: ⁻ support:	Magdalena Latos, e-mail: latos.magdalena93@gmail.com Departmental sources	
Back Material/N	ground: lethods:	pulmonary function (as measured by spirometry and ed consistently with bronchoscopic interventions (BIs the 1-year follow-up visit. Fifty patients who underwent primary double-lung tr a single center (23 who received BIs and 27 who did tion was assessed with spirometry, based on forced both measured in liters (L) and percentages (%), and	enosis (AS). The aim of this study was to assess whether a 6-minute walk test [6MWT]) in patients with AS treat-) was comparable to that in their AS-free counterparts at ansplantation between January 2015 and March 2019 at not) were enrolled in this retrospective study. Graft func- expiratory volume (FEV ₁) and forced vital capacity (FVC), the Tiffeneau-Pinelli index (FEV ₁ /FVC), and a 6MWT and
	Results: lusions:	their first post-transplant year. Airway obstruction wa 65.23% of those who did receive the interventions. T lations pertaining to the number of balloon BIs and BIs and 1-year FEV ₁ /FVC (r_s =0.72). A statistically sign between the number of balloon bronchoplasty treatments	compared with individuals who did not receive BIs during as present in 22% of patients who did not receive BIs and here were statistically significant, strong, negative corre- 1-year FEV ₁ % (r_s =0.67) as well as the number of balloon nificant, strong, negative correlation (r_s =0.75) was found
			may recur or persist despite use of various procedures.
MeSH Ke	ywords:	Airway Management • Bronchoscopy • Lung Trans	splantation • Respiratory Function Tests
Full-t	ext PDF:	https://www.annalsoftransplantation.com/abstract/	index/idArt/927025
		🛱 1762 🏥 3 🛄 🖬 💻	2 11



Background

Lung transplantation is the ultimate treatment for patients with end-stage lung disease. The survival rate after the procedure is good, with 50% of patients living 7.8 years after double-lung transplantation [1]. The procedure also is associated with improved pulmonary function and exercise capacity [2]. However, a significant number of double-lung recipients do not achieve 80% of predicted forced vital capacity (FVC) during their first post-transplant year [3]. In some cases, the finding can be explained by a ventilatory defect caused by airway complications located in bronchial anastomoses [4,5]. Prevalence is reported to range from 10% to 33%, but most experts agree that such complications occur in approximately 15% of lung transplant recipients [4,6,7]. Many factors, such as graft ischemic time and pretransplant microbiological colonization, can contribute to development of airway stenosis (AS) [5,6]. During the posttransplant period, patients may experience airway complications such as bronchial stenosis, exophytic necrotic tissue, and bronchomalacia [5]. Bronchoscopic interventions (BIs) available include balloon bronchoplasty, cryotherapy, argon plasma coagulation, and laser therapy; in some cases, airway stenting is a last resort [4]. Even though AS does not influence survival in graft recipients, it can cause persistent airflow limitation despite frequent use of BIs [8]. Questions remain about whether Bls used to treat AS can improve a patient's ventilation permanently and whether these measures can improve spirometry results such that they are comparable to those in lung recipients who do not have AS. The aim of the present study was to assess whether pulmonary function (as measured by spirometry and a 6-minute walk test [6MWT]) in patients with AS treated consistently with BIs was comparable to that in their AS-free counterparts at the 1-year follow-up visit.

Material and Methods

This retrospective study included 50 patients who underwent primary double-lung transplantation between January 2015 and March 2019 in our facility and had reached at least 1-year follow-up. The inclusion criteria were transplantation at age 15 years or older and absence during the study period of conditions or related procedures that would influence lung function, such as acid reflux, fundoplication surgery, and musculoskeletal disorders. Exclusion criteria were single-lung transplantation, retransplantation during the follow-up period, and existence of conditions such as a significant aortic aneurysm that would prevent performance of pulmonary function testing during the study follow-up. Detailed characteristics of the patients are listed in **Table 1**.

In the present study, graft function was assessed with spirometry and the Tiffeneau-Pinelli index and measurement of oxygen saturation before and after a 6MWT. Spirometry consisted of measurement of forced expiratory volume (FEV₁) and forced vital capacity (FVC), both in liters (L) and percentages (%). The Tiffeneau-Pinelli index is FEV₁/FVC. All of the tests were performed on the first day of patient admission for the 1-year follow-up visit after lung transplantation. Any Bls were performed after the testing because the aim of the study was to assess lung function 1 year after lung transplantation. Airway obstruction was defined as FEV₁/FVC <70%. Results obtained from 6MWTs that were terminated for non-pulmonary reasons, such as a significant increase in blood pressure or active musculoskeletal injury of the lower limbs, were excluded from the study.

The primary endpoint of the study was to assess whether there was a difference in pulmonary function in patients who required BIs. The study group was divided into 2 groups: patients who did not undergo BI and those who had \geq 1 BI during the first year after transplantation. BI was performed mainly by means of balloon dilation, but cryotherapy, laser therapy, and argon plasma coagulation also were used. Hypertrophic stenoses of the bronchial anastomoses in the course of complicated healing were the main reason for the aforementioned treatment. None of the patients experienced bronchial dehiscence.

Statistical analysis was carried out using TIBCO Statistica 13.30 software, including assessment of basic statistics and Shapiro-Wilk tests. A *t* test and Mann-Whitney U test were performed as appropriate. Correlation analyses based on the nonparametric Spearman rank correlation coefficient (r_s) were performed to analyze the relationship between variables. The classic threshold for significance was α =0.05.

Results

Twenty-three of 50 patients assessed during 1-year followup required ≥ 1 BI that involved, at a minimum, balloon bronchoplasty. The mean number of BIs in the study population was 6.78±5.89 (minimum 1, maximum 19). The primary endpoint of the study was to assess whether patients who underwent ≥ 1 BI during the first year had worse results on pulmonary function tests performed during the routine check-up visit 1 year after lung transplantation. Spirometry parameters such as FEV₁, FVC, and the Tiffeneau-Pinelli index were evaluated. Detailed results of testing are shown in Table 2. Patients who underwent BIs because of significant AS had significantly lower FEV,% compared with those without BI during their first post-transplant year. Similar results were demonstrated for mean FVC%. Airway obstruction was present in 22% of patients without BI as well as 65.23% of those with a history of BI. Median values for the Tiffeneau-Pinelli index differed significantly in patients, depending on their BI status, as shown

Studied group (n=50)	Patients without BI (n=27)	Patients with BI (n=23)	p Value
Age at transplantation [ME±IQR]	40.00±8.00	39.00±5.00	0.529
BMI at transplant [M±SD]	23.34±2.56	24.17±3.67	0.365
RBC at qualification [ME±IQR]	4.89000±0.48	4.88±0.63	0.683
HGB at qualification [ME±IQR]	11.7±5.40	10.30±3.65	0.592
FEV ₁ [%] at qualification [ME±IQR]	23.40±11.00	27.00±14.00	0.311
FVC [%] at qualification [M±SD]	47.98±23.55	45.54±15.14	0.732
RBC 1 year [M±SD]	3.92±0.46	3.87±0.57	0.702
HGB 1 year [M±SD]	7.25±0.78	7.39±1.00	0.594
GFR 1 year [ME±IQR]	67.19±43.69	57.38±26.23	0.741
Gender as percentage of male participants	51.85%	47.82%	
Underlying disease [%]			
CF	48.16%	43.48%	
IPAH	14.81%	8.70%	
ILD	14.81%	17.39%	
COPD	22.22%	26.09%	
Other	0.00%	4.35%	

Table 1. General characteristics of patients included in the study.

6MWT - 6-minute walk test; BI - bronchoscopic intervention; BMI - body mass index; CF - cystic fibrosis; COPD - chronic obstructive pulmonary disease; FEV, - forced expiratory volume in 1 second; FEV,/FVC - Tiffeneau-Pinelli index; FVC - forced vital capacity; GFR – glomerular filtration rate; HGB – hemoglobin; IPAH – idiopathic pulmonary arterial hypertension; ILD – interstitial lung disease; IQR – interquartile range; M – mean; Me – median; post-sat – oxygen saturation at the end of 6-minute walk test; pre-sat – oxygen saturation measured at the beginning of 6-minute walk test; RBC - red blood cells; SD - standard deviation.

Table 2. Pulmonary function tests at 1-year follow-up in patients with or without bronchoscopic interventions.

	Patients without BI (n=27)	Patients with BI (n=23)	p-Value
FEV ₁ % [M±SD]	81.3333±26.8958	54.3913±20.88875	0.000
FEV ₁ /FVC [Me±IQR]	78.00000±18.00000	62.00000±32.00000	0.004*
FVC% [M±SD]	87.8519 <u>±</u> 20.4426	75.2174±19.28956	0.030
6MWT distance [M±SD]	509.2370±100.7069	522.0435±79.74776	0.625
6MWT pre-sat [%][M±SD]	98.3333±1.4676	97.5652±1.16096	0.048
6MWT post-sat [%] [M±SD]	95.7778±2.5770	94.5652±2.72740	0.113

* p-Value was assessed by U-Mann Whitney test. All other p-values are the result of t-student tests; 6MWT – 6-minute walk test; BI – bronchoscopic intervention; FEV, – forced expiratory volume in 1 second; FEV,/FVC – Tiffeneau-Pinelli index; FVC – forced vital capacity; IQR - interquartile range; M - mean; Me - median; post-sat - oxygen saturation at the end of 6-minute walk test; pre-sat - oxygen saturation measured at the beginning of 6-minute walk test; SD - standard deviation.

in Table 2. During every follow-up visit, our patients perform the 6MWT. There was no statistically significant difference between the groups in distance achieved on this test. However, oxygen saturation measured before the test was notably lower in the patients who had undergone ≥1 BI during their first post-transplant year. A comparison of the 6MWT results is shown in Table 2.

Further investigations were performed to establish whether there was a connection between BI and results of pulmonary function tests. Our analyses were based on a Spearman rank correlation coefficient, as shown in Table 3. The impact on spirometry parameters of the number of BIs involving at least balloon B was established. There were statistically significant, strong, negative correlations between the number of balloon BIs and 1-year FEV₁% (r_s =0.67) and the number of balloon BIs

No.	Studied pair of variables	rs	5	p
1	Number of BBI & 1-year FEV ₁ [%]	-0.67	3386.81	<0.001
2	Number of BBI & 1-year FEV ₁ /FVC	-0.72	3487.04	<0.001
3	Number of BBI & 1-year 6MWTpost-sat [%]	-0.46	2963.04	0.026
4	Number of BBI & 2-year FEV ₁ [%]	-0.41	169.21	0.273
5	Number of BBI & 2-year FEV ₁ /FVC	-0.49	179.25	0.177
6	Number of BBI & 2-year 6MWT post-sat [%]	-0.75	210.13	0.02
7	1-year FEV ₁ [%] & 2-year FEV ₁ [%]	0.92	10.0	0.001
8	1-year FEV ₁ /FVC & 2-year FEV ₁ /FVC	0.92	10.0	0.001
9	1-year FEV ₁ [%] & 1-year 6MWT post-sat [%]	0.52	977.7	0.012
10	1-year FEV ₁ /FVC & 1-year 6MWTpost-sat [%]	0.65	708.06	0.001

Table 3. Correlation coefficients with corresponding Spearman's rank (r_c), statistics (S), and P values.

6MWT – 6-minute walk test; BBI – bronchoscopic interventions involving at least balloon bronchoplasty performed during the first year of follow-up after double lung transplantation; FEV₁ – forced expiratory volume in 1 second; FEV₁/FVC – Tiffeneau-Pinelli index; FVC – forced vital capacity; post-sat – oxygen saturation at the end of 6-minute walk test; pre-sat – oxygen saturation measured at the beginning of 6-minute walk test.

and 1-year FEV₁/FVC (r_s =0.72). Balloon BI did not have an effect on 1-year FVC%.

Discussion

No correlation was found between the number of balloon BIs and distance on the 6MWT. However, the aforementioned analyses showed that there was a statistically significant, moderate, negative correlation (r_s =0.46) between balloon BI and oxygen saturation measured at the end of the 6MWT (6MWT post-sat). Spirometry parameters such as FEV₁% and FEV₁/FVC also had a statistically significant, strong, positive correlation with 6MWT post-sat.

The data gathered allowed the researchers to assess whether balloon BI would also influence spirometry results at 2-year follow-up; the differences in those outcomes were not statistically significant. Nevertheless, we found that the more balloon BIs patients undergo, the worse their 6MWT post-sat may be at the 2-year check-up visit (statistically significant, strong, negative correlation of r_s =0.75).

Our clinical observations led us to statistically test whether there was a chance of improvement in the pulmonary function tests over time. We found statistically significant, very strong, positive correlations between FEV₁% obtained at 1 and 2 years (r_s =0.92). This means that patients who underwent BI during the first year will most likely have similar FEV₁% in the first and second years after transplant. We made the same observation in regard to FEV₁/FVC (r_s =0.92). Spirometry is considered to be the cornerstone of graft function monitoring [3]. Our study revealed that in patients who required ≥ 1 BI during their first post-transplant year, spirometry parameters were statistically significantly lower than in patients who did not need such bronchoscopic treatment. A similar finding was reported by Mazzetta et al. [8], who found that patients with central AS so severe it required BI had lower FEV₁ (L) and FEV₁/FVC at 18-month follow-up (81±13% versus 61±14%, *P*<0.001).

Our study assessed patients during the first visit after reaching 1-year follow-up. We also reported a statistically significant difference between our study groups in FEV₁ (%) between our study groups ($81\pm27\%$ versus $54\pm21\%$, P<0.001) and FEV₁/FVC ($78\pm18\%$ versus $62\pm32\%$, P=0.004). Mazzetta et al. also showed that CAS does not affect the survival of lung transplant recipients [8]. That is supported by a paper published by Shofer et al. [7]. In contrast, Mohanka et al. found that failure to achieve FVC $\geq 80\%$ was an independent risk factor for 3-year mortality [3].

In our study, patients who required BI reported significantly lower FVC% than their BI-free counterparts ($75\pm19\%$ versus $88\pm20\%$, P=0.03). Thirty percent of BI-free patients did not achieve FVC \geq 80%, compared with 52% of those who required BI. Our study also indicates that the more balloon bronchoplasty procedures patients require during the first post-transplant year, the worse spirometry parameters they may present at 1- and 2-year follow-up because the aforementioned statistical analyses showed a strong, negative correlation between BI and those parameters. As described by Sinha, even though balloon bronchoplasty alone provides intermediate improvement, its effects are not long-lasting. In some cases, AS dilatation may be needed every 2 to 4 weeks [9]. It seems that BI other than stenting is only a palliative measure for maintaining airway patency. As reported by Shofer et al., only 37% of patients will have resolution of bronchial complications with bronchoplasty alone, and, ultimately, more than 50% of those individuals will require airway stenting [7]. Improvement in ventilation as assessed by spirometry has been reported after stent placement [10]. However, this therapeutic method is not free from adverse effects. Stent placement reportedly is associated with mucus plugging, ingrowth of granulation tissue, and microbiological colonization and harm when a stent migrates [9]. That is why AS stenting should be a last-resort treatment [11].

To the best of our knowledge, no reports exist about the influence of AS and BI on exercise capacity assessed by the 6MWT. It is important to note that the worse a patient's FEV_1 % at 1-year follow-up, the worse his or her oxygen saturation after the 6MWT is likely to be. This finding may have clinical implications because it indicates that unsatisfactory ventilation is connected with oxygen deficit during exercise. The distance on the 6MWT did not differ between our study groups.

References:

- 1. Chambers D, Cherikh W, Harhay M et al: The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report — 2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant, 2019; 38(10):1042–55
- 2. Bartels M, Armstrong H, Gerardo R et al: Evaluation of pulmonary function and exercise performance by cardiopulmonary exercise testing before and after lung transplantation. Chest, 2011; 140(6):1604–11
- 3. Mohanka MR, Kanade R, Garcia H et al: Significance of best spirometry in the first year after bilateral lung transplantation: Association with 3-year outcomes. Transplantation, 2020; 104(8): 1712–19
- Varela A. Hoyos L, Romero A et al: Management of bronchial complications after lung transplantation and sequelae. Thorac Surg Clin, 2018; 28(3): 365–75
- Mahajan AK, Folch E, Khandhar SJ et al: The diagnosis and management of airway complications following lung transplantation. Chest, 2017; 152(3): 627–38

Because every bronchoscopic technique has adverse effects, such procedures should only be performed in carefully selected patients [9].

Conclusions

Bls without stenting may result in temporary improvement in individuals who have undergone primary double-lung transplantation. Despite use of these therapies, however, patients who experience bronchial stenosis may not obtain expected long-term improvement in ventilatory parameters at the 1-year follow-up visit. It is notable that CAS can recur or persist even when various Bls are used. The present study also suggests that unsatisfactory ventilation may be connected with oxygen deficit during exercise. The number of balloon bronchoplasty procedures a patient has undergone may be associated with worse results obtained during spirometry and on the 6MWT. Further study is required.

Conflicts of interest

None.

- Yserbyt J, Dooms C, Vos R et al: Anastomotic airway complications after lung transplantation: Risk factors, treatment modalities and outcome – a single-centre experience. Eur J Cardiothoracic Surg, 2016; 49(1): e1–8
- 7. Shofer SL, Wahidi MM, Davis WA et al: Significance of and risk factors for the development of central airway stenosis after lung transplantation. Am J Tranplant, 2013; 13(2): 383–89
- Mazzetta A, Porzio M, Riou M et al: Patients treated for central airway stenosis after lung transplantation have persistent airflow limitation. Ann Transplant, 2019; 24: 84–92
- Sinha N: Transplant pulmonary interventions: Translating lung transplant interventions to nontransplant patients. Methodist Debakey Cardiovasc J, 2016; 12(4): 18–20
- Chhajed PN, Malouf MA, Tamm M et al: Interventional bronchoscopy for the management of airway complications following lung transplantation. Chest, 2001; 120(6): 1894–99
- 11. Frye L, Machuzak M: Airway Complications after lung transplantation. Clin Chest Med, 2017; 38(4): 693–706